Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Compass Therapeutics (CMPX) PT Lowered to $7 at Jefferies
May 13, 2024 1:21 PM EDTJefferies analyst Maury Raycroft lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $7.00 (from $8.00) while maintaining a Buy rating.
The analyst comments "CMPX updated pivotal BTC ph.II/III data guidance to 1Q25 (vs YE24), which we think is incremental given that enrollment... More
